Please try another search
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Robert L. Van Nostrand | 64 | 2017 | Independent Director |
Jeffrey S. Weber | - | 2016 | Chairman of Scientific Advisory Board |
Angelos M. Stergiou | 45 | 2012 | Founder, President, CEO & Director |
John W. Varian | 61 | 2017 | Independent Director |
Jane Wasman | 65 | 2017 | Independent Chairman |
Larry W. Kwak | - | 2015 | Member of Scientific Advisory Board |
David A. Scheinberg | 68 | 2015 | Independent Director |
Javier Pinilla-Ibarz | - | 2016 | Member of Scientific Advisory Board |
Guenther Koehne | - | - | Member of Scientific Advisory Board |
Sattva S. Neelapu | - | - | Member of Scientific Advisory Board |
Katherine Bach Kalin | 61 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review